Copyright Reports & Markets. All rights reserved.

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by Product
      • 1.4.2 Serum biomarkers
      • 1.4.3 Hepatic fibrosis biomarkers
      • 1.4.4 Apoptosis biomarkers
      • 1.4.5 Oxidative stress biomarkers
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by End User
      • 1.5.2 Pharma & CRO Industry
      • 1.5.3 Hospitals
      • 1.5.4 Diagnostic Labs
      • 1.5.5 Academic Research Institutes
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size
      • 2.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2014-2025
      • 2.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2014-2025
    • 2.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Growth Rate by Regions
      • 2.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Regions
      • 2.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Manufacturers
      • 3.1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Manufacturers
      • 3.1.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturers
      • 3.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Concentration Ratio (CR5 and HHI)
    • 3.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturers
      • 3.2.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturers (2014-2019)
      • 3.2.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Manufacturers (2014-2019)
    • 3.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Manufacturers
    • 3.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base Distribution, Product Types
      • 3.4.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Type
      • 3.4.3 Date of International Manufacturers Enter into NASH (Non-alcoholic Steatohepatitis) Biomarkers Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Product
    • 4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Product
    • 4.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Breakdown Data by End User

    6 North America

    • 6.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers by Countries
      • 6.1.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Countries
      • 6.1.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers by Product
    • 6.3 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers by End User

    7 Europe

    • 7.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers by Countries
      • 7.1.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Countries
      • 7.1.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers by Product
    • 7.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers by End User

    8 Asia Pacific

    • 8.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers by Countries
      • 8.1.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Countries
      • 8.1.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers by Product
    • 8.3 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers by End User

    9 Central & South America

    • 9.1 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers by Countries
      • 9.1.1 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Countries
      • 9.1.2 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers by Product
    • 9.3 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers by Countries
      • 10.1.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Countries
      • 10.1.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers by Product
    • 10.3 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers by End User

    11 Company Profiles

    • 11.1 GENFIT SA
      • 11.1.1 GENFIT SA Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.1.5 GENFIT SA Recent Development
    • 11.2 Gilead Sciences, Inc. (GILD)
      • 11.2.1 Gilead Sciences, Inc. (GILD) Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.2.5 Gilead Sciences, Inc. (GILD) Recent Development
    • 11.3 AstraZeneca
      • 11.3.1 AstraZeneca Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.3.5 AstraZeneca Recent Development
    • 11.4 Novartis AG
      • 11.4.1 Novartis AG Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.4.5 Novartis AG Recent Development
    • 11.5 Bristol-Myers Squibb Company
      • 11.5.1 Bristol-Myers Squibb Company Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.5.5 Bristol-Myers Squibb Company Recent Development
    • 11.6 Allergan Plc
      • 11.6.1 Allergan Plc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.6.5 Allergan Plc Recent Development
    • 11.7 Novo Nordisk A/S
      • 11.7.1 Novo Nordisk A/S Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.7.5 Novo Nordisk A/S Recent Development
    • 11.8 Boehringer Ingelheim
      • 11.8.1 Boehringer Ingelheim Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.8.5 Boehringer Ingelheim Recent Development
    • 11.9 Pfizer Inc
      • 11.9.1 Pfizer Inc Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
      • 11.9.5 Pfizer Inc Recent Development

    12 Future Forecast

    • 12.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Forecast by Regions
      • 12.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Regions 2019-2025
      • 12.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Regions 2019-2025
    • 12.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Forecast by Product
      • 12.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Product 2019-2025
      • 12.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Product 2019-2025
    • 12.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Forecast by End User
    • 12.4 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast
    • 12.5 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast
    • 12.6 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast
    • 12.7 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast
    • 12.8 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the NASH (Non-alcoholic Steatohepatitis) Biomarkers market based on company, product type, end user and key regions.

      This report studies the global market size of NASH (Non-alcoholic Steatohepatitis) Biomarkers in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of NASH (Non-alcoholic Steatohepatitis) Biomarkers in these regions.
      This research report categorizes the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market by top players/brands, region, type and end user. This report also studies the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      GENFIT SA
      Gilead Sciences, Inc. (GILD)
      AstraZeneca
      Novartis AG
      Bristol-Myers Squibb Company
      Allergan Plc
      Novo Nordisk A/S
      Boehringer Ingelheim
      Pfizer Inc

      Market size by Product
      Serum biomarkers
      Hepatic fibrosis biomarkers
      Apoptosis biomarkers
      Oxidative stress biomarkers
      Others
      Market size by End User
      Pharma & CRO Industry
      Hospitals
      Diagnostic Labs
      Academic Research Institutes

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of NASH (Non-alcoholic Steatohepatitis) Biomarkers market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global NASH (Non-alcoholic Steatohepatitis) Biomarkers companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of NASH (Non-alcoholic Steatohepatitis) Biomarkers submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of NASH (Non-alcoholic Steatohepatitis) Biomarkers are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of NASH (Non-alcoholic Steatohepatitis) Biomarkers market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now